NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), announced today that its PGxHealth™ division, provider of Therapeutic Diagnostics™, has launched a new test, PGxPredict™:RITUXIMAB, further strengthening its leadership position within the rapidly evolving fields of pharmacogenetics and molecular diagnostics. This is the second pharmacogenetic test of its kind launched by PGxHealth this month. The assay is based on a worldwide exclusive license to an intellectual property portfolio from Innate Pharma S.A. of Marseille, France.
